P-328: Long-term survival of Multiple Myeloma patients in Brazil

Introduction: : Multiple myeloma (MM) is a rare neoplasm. Its incidence in Brazil, in 2020, was 2.4/100,000 in males and 1.7/100,000 in females. Mortality ranged from 1.8 to 1.2/100,000. In Latin America, in patients eligible for autologous stem-cell transplantation (ASCT), overall survival (OS) was 56.0% in five years, whereas in non-transplant individuals it was 38.0%.

Methods: Data were sourced from the São Paulo Oncocentro Foundation (FOSP) database, including MM cases from São Paulo state, between 2000 to 2018. OS was calculatedfrom the date of diagnosis until the date of death or last available information. OS curves were generated using the Kaplan-Meier method, compared using the log-rank test, and prognostic factors determiated by Cox regression, hazard ratio (HR), a significance level of 5%, using the SPSS v.25.

Results: The study cohort comprised MM patients with a median age of 63.5 years. Five- and ten-year OS rates were 43.8% and 26.1% (< 60 years) and 28.2% and 11.0% (≥60 years). Notably, patients with health insurance showed higher OS rates compared to those in the public system, the five- and ten-year OS for health insurance were 59.4% and 31.8%, versus 35.3% and 17.2% for public system. For those undergoing ASCT, five-year OS was similar in both sexes (62.9% males, 60.4% females); < 60 years age group had a 64.1% five year and 40.0% the ten-year OS. Non-ASCT patients showed lower rates 36.8% and 21.1% at five- and ten-years. Among non-ASCT patients over 60 years health insurance, five-year OS was 56.6%, versus26.1% for public healthcare, for ten-year OS was 24.3% versus 10.0%, respectively. Survival rates improved from 2010-2018, notably among transplant recipients:018 59.9% and 30.5% (five and ten years) vs 27.2% and 13.1%.

Conclusions: MM survival in São Paulo has increased over five- and ten years, but disparities persist. Improved access to diagnosis and treatment is essential to reduce inequalities and enhance patient outcomes.